Cortechs.ai Receives Health Canada Approval to Expand Sales of AI-Powered Imaging Solutions in North America

SAN DIEGO, April 23, 2025 /PRNewswire/ — Cortechs.ai, a global leader in AI-driven medical imaging analysis, is proud to announce that that it has received approval from Health Canada for the sale of its innovative suite of imaging solutions. This regulatory milestone marks a significant expansion of Cortechs.ai’s presence in the Canadian healthcare market and reinforces its commitment to enhancing clinical diagnostics and radiology workflows worldwide.

Cortechs.ai’s advanced portfolio includes NeuroQuant^®, NeuroQuant^® MS, OnQ™ Prostate, and NeuroQuant^® Brain Tumor. These software tools harness advanced AI to streamline complex imaging analysis, equipping clinicians with accurate insights that enhance disease assessment and validation across various care pathways.

NeuroQuant^® and NeuroQuant^® MS offer automated segmentation and volumetric analysis of brain MRI, aiding in the assessment and monitoring of neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis. NeuroQuant^® Brain Tumor delivers quantitative MR imaging analysis to assist clinicians in interpreting neurological MR images when evaluating brain tumors, while OnQ™ Prostate enhances prostate MRI interpretation, allowing for a more precise evaluation of prostate cancer.

“This Health Canada approval is a monumental achievement for Cortechs.ai and a testament to our dedication to transforming diagnostic imaging,” said Jared Dixon, VP of Global Sales at Cortechs.ai. “Expanding access to our AI-powered solutions in Canada means that more clinicians will have the tools they need to make faster, more accurate diagnoses and improve patient outcomes. This is a major step forward for our company’s growth and our mission to revolutionize disease detection and treatment across the globe.”

With this approval, Cortechs.ai is poised to collaborate with healthcare providers and institutions across Canada, equipping them with cutting-edge solutions that optimize clinical workflows and elevate patient care.

For more information about Cortechs.ai and its cutting-edge imaging solutions, visit www.cortechs.ai.

About Cortechs.ai 

Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients.

The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer.

Cortechs.ai’s industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.

For more information, please contact:

info@cortechs.ai 

+1 858 459 9700

View original content to download multimedia:https://www.prnewswire.com/news-releases/cortechsai-receives-health-canada-approval-to-expand-sales-of-ai-powered-imaging-solutions-in-north-america-302435287.html

SOURCE Cortechs.ai